A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Trial Details

NCT ID
NCT04988555
Phase
PHASE1 / PHASE2
Sponsor
Sumitomo Pharma America, Inc.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Enzomenib
  • azoles
  • Venetoclax
  • Gilteritinib
  • Azacitidine (AZA)
  • Intensive chemotherapy with 7 + 3
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • Palo Alto, California, United States|37.44188,-122.14302
  • Denver, Colorado, United States|39.73915,-104.9847
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • For patients in Phase I:
  • Have a diagnosis of relapsed or refractory AML, ALL or acute leukemia of ambiguous lineage according to World Health Organization (WHO) 2022 classi…
  • For patients with MDS (selected sites and regions):
  • Patients with MDS must have bone marrow blasts ≥ 5%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →